OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers
Open Access
- 6 January 2010
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 35 (1), 99-104
- https://doi.org/10.1111/j.1365-2710.2009.01071.x
Abstract
Purpose: To investigate the contribution of the most frequent single nucleotide polymorphism (SNPs) of the organic anion transporting polypeptide 1B1 (OATP1B1) 388A>G to the pharmacokinetics of pitavastatin in Chinese healthy volunteers. Methods: Eighteen healthy volunteers participated in this study. Group 1 consisted of nine subjects who were of 388AA wild‐type OATP1B1 genotype. Group 2 consisted of seven subjects with the 388GA genotype and two 388GG homozygotes. Two milligram of pitavastatin was administered orally to the volunteers. The plasma concentration of pitavastatin was measured for up to 48 h by liquid chromatography–mass spectrometry (LC–MS). Results: The pharmacokinetic parameters of pitavastatin were significantly different between the two genotyped groups. The concentration (Cmax) value was higher in the 388GA + 388GG group than that in the 388AA group (39·22 ± 8·45 vs. 22·90 ± 4·03 ng/mL, P = 0·006). The area under the curve to the last measurable concentration (AUC0–48) and area under the curve extrapolated to infinity (AUC0–∞) of pitavastatin were lower in the 388AA group than in the 388GA + 388GG group (100·42 ± 21·19 vs. 182·19 ± 86·46 ng h/mL, P = 0·024; 108·12 ± 24·94 vs. 199·64 ± 98·70ng h/mL, P = 0·026) respectively. The oral clearance (Cl/F) was lower in the 388GA + 388GG group than that in the 388AA group (12·46 ± 4·79 vs. 19·21 ± 3·74/h, P = 0·012). The elimination of half‐life (t1/2) and peak concentration times (Tmax) values showed no difference between these groups. Conclusions: The OATP 388A>G polymorphism causes significant alterations in the pharmacokinetics of pitavastatin in healthy Chinese volunteers and this may well be clinically significant.Keywords
This publication has 17 references indexed in Scilit:
- Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populationsClinica Chimica Acta; International Journal of Clinical Chemistry, 2008
- Global Analysis of Genetic Variation in SLCO1B1Pharmacogenomics, 2007
- Organic anion transporting polypeptide-1B1 haplotypes in Chinese patientsActa Pharmacologica Sinica, 2007
- SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy VolunteersCancer Cell, 2007
- Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populationsEuropean Journal of Clinical Pharmacology, 2007
- Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functionsPharmacology & Therapeutics, 2006
- Ethnic differences in statin dispositionClinical Pharmacology & Therapeutics, 2005
- Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteersCancer Cell, 2005
- Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in HumansJournal of Pharmacology and Experimental Therapeutics, 2004
- Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonizationXenobiotica, 2003